Clinical Trial: RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06397313) titled 'RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis' on April 29.

Brief Summary: The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patient with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.

Study Type: Interventional

Condition: Myelofibrosis

Intervention: * Drug: RVU120

RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

Other Name: SEL120

* Drug...